1. Pink Sheet
  2. >>Compliance
  3. >>Manufacturing

FDA’s OPQ Chief Tells Generic Drug Makers Its Time To Up Their Quality Game

 
• By Joanne S. Eglovitch

The head of US FDA’s drug quality office comments on quality-related topics at the GRx-Biosims meeting; sheds more light on facility rating system plan.

FDA entrance sign 2016
The Office of Pharmaceutical Quality is about to celebrate five-year anniversary. • Source: Shutterstock

The director of the US Food and Drug Administration’s drug quality office, Michael Kopcha, said that a reorganization within the Office of Pharmaceutical Quality reflects an even-more targeted focus on drug quality, and urged the generic drug industry to take a similarly focused approach in addressing manufacturing quality.

During his presentation to the Association for Accessible Medicines GRx-Biosims conference in Bethesda, Md, on 5 November, Kopcha also shed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

More from Compliance

‘Sex Pill For Women’: Sprout CEO’s Addyi Instagram Post Draws US FDA Warning Letter

 
• By Sue Sutter

Cindy Eckert’s social media post with a People.com story failed to include any risk information, made misleading representations about benefits and omitted material information about the indication, said the agency, which flagged similar concerns about an Addyi radio ad five years ago.

UK MHRA: Bacteriophage Developers Wanted ‘More Clarity’ On UK Framework

 
• By Eliza Slawther

Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.

Novo, Lilly Ad Challenges Cause Discontinued Claims For Compounded GLP-1s

 
• By Sue Sutter

Two pharmacies, a medical spa and a telehealth company voluntarily removed efficacy, safety and quality claims for compounded GLP-1 products after innovator companies filed challenges with the National Advertising Division.